Edwards Lifesciences jumps on raised 2026 sales guidance, Q2 beats
Seeking Alpha ·
Edwards Lifesciences ( EW ) is up ~7% in after-hours trading Thursday after posting Q2 results that beat on both lines and boosting revenue expectations for the year. The company now sees 2026 revenue of $6.6B-$6.9B, up from $6.5B-$6.9B. Consensus is $6.74B.
DYAX Investor Sentiment
Bullish (Long) 32% · Bearish (Short) 68%
378 participants
Related News
- Grupo Televisa reports Q2 results
- Summit Therapeutics says cash crunch could impact its ability to continue
- Civista signals mid-single-digit 2026 loan growth as CEO transition begins next month
- PG&E targets 9%+ annual EPS growth through 2030 while reaffirming no new equity needs
- S&T Bancorp anticipates mid-single-digit loan growth for 2026, while adding $100M buyback authorization
- Southwest projects 2026 adjusted EPS of $3.25 to $4.25 as unit revenue growth outlook remains high
